Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 16787
Country/Region: Tanzania
Year: 2016
Main Partner: John Snow, Inc
Main Partner Program: NA
Organizational Type: Implementing Agency
Funding Agency: USAID
Total Funding: $8,860,864 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $40,452
Care: Pediatric Care and Support (PDCS) $25,700
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $7,214,559
Testing: HIV Testing and Counseling (HVCT) $326,479
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $254,602
Treatment: Adult Treatment (HTXS) $928,912
Treatment: Pediatric Treatment (PDTX) $70,160
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 350
HTS_TST Age/sex: 1-9 2017 1,097
HTS_TST Age/sex: 10-14 Female 2017 406
HTS_TST Age/sex: 10-14 Male 2017 340
HTS_TST Age/sex: 15-19 Female 2017 800
HTS_TST Age/sex: 15-19 Male 2017 488
HTS_TST Age/sex: 20-24 Female 2017 1,305
HTS_TST Age/sex: 20-24 Male 2017 350
HTS_TST Age/sex: 25-49 Female 2017 5,985
HTS_TST Age/sex: 25-49 Male 2017 3,383
HTS_TST Age/sex: 50+ Female 2017 670
HTS_TST Age/sex: 50+ Male 2017 721
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 36,669
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 102,647
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 114,193
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 78,218
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 347,622
HTS_TST Service Delivery Point (Community): Homebased testing 2017 8,193
HTS_TST Service Delivery Point (Community): Mobile testing 2017 25,885
HTS_TST Service Delivery Point (Facility): Inpatient 2017 6,756
HTS_TST Service Delivery Point (Facility): Other PITC 2017 6,088
HTS_TST Service Delivery Point (Facility): Outpatient 2017 71,437
HTS_TST Service Delivery Point (Facility): Pediatric 2017 43,972
HTS_TST Service Delivery Point (Facility): PMTCT 2017 13,232
HTS_TST Service Delivery Point (Facility): VMMC 2017 172,267
HTS_TST Sum of Age/Sex disaggregates 2017 14,448
HTS_TST Sum of Aggregated Age/Sex <15 2017 139,316
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 192,411
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 331,727
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 23
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 10
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 54
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 32
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 91
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 27
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 415
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 239
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 47
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 50
HTS_TST_POS Test Result by Age: Positive: <1 2017 18
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 47
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 686
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 852
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 6,425
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,721
PMTCT_ART Already on ART at beginning of current pregnancy 2017 278
PMTCT_ART New on ART 2017 539
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 12,709
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 646
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 176
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 6
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 18
PMTCT_EID Sum of Infant Age disaggregates 2017 822
PMTCT_STAT By: Known positives at entry 2017 293
PMTCT_STAT By: Number of new positives identified 2017 572
PMTCT_STAT Number of new ANC and L&D clients 2017 13,375
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 12,709
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 2
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 5
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 20
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 6
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 14
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 27
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 45
PMTCT_STAT Sum of Positives Status disaggregates 2017 865
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 103
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 224
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 493
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 877
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 8
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 169
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 1
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 154
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 14
TB_SCREENDX Screen Result: Screened Positive for TB 2017 169
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 7,067
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 2,662
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 364
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 326
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 10,419
TX_CURR Age/Sex: <1 2017 2
TX_CURR Age/Sex: <1-9 2017 152
TX_CURR Age/Sex: 10-14 Female 2017 35
TX_CURR Age/Sex: 10-14 Male 2017 38
TX_CURR Age/Sex: 15-19 Female 2017 222
TX_CURR Age/Sex: 15-19 Male 2017 104
TX_CURR Age/Sex: 20-24 Female 2017 476
TX_CURR Age/Sex: 20-24 Male 2017 18
TX_CURR Age/Sex: 25-49 Female 2017 2,204
TX_CURR Age/Sex: 25-49 Male 2017 473
TX_CURR Age/Sex: 50+ Female 2017 194
TX_CURR Age/Sex: 50+ Male 2017 142
TX_CURR Aggregated Age/Sex: <15 Female 2017 208
TX_CURR Aggregated Age/Sex: <15 Male 2017 209
TX_CURR Aggregated Age/Sex: 15+ Female 2017 4,880
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,617
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 10,974
TX_CURR Sum of age/sex disaggregates 2017 326
TX_CURR Sum of Aggregated Age/Sex <15 2017 417
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 6,497
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 6,914
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 130
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 77
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,336
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 729
TX_NEW By Age/Sex: <1 2017 2
TX_NEW By Age/Sex: 1-9 2017 82
TX_NEW By Age/Sex: 10-14 Female 2017 29
TX_NEW By Age/Sex: 10-14 Male 2017 17
TX_NEW By Age/Sex: 15-19 Female 2017 189
TX_NEW By Age/Sex: 15-19 Male 2017 88
TX_NEW By Age/Sex: 20-24 Female 2017 295
TX_NEW By Age/Sex: 20-24 Male 2017 13
TX_NEW By Age/Sex: 25-49 Female 2017 1,260
TX_NEW By Age/Sex: 25-49 Male 2017 378
TX_NEW By Age/Sex: 50+ Female 2017 128
TX_NEW By Age/Sex: 50+ Male 2017 101
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 5,854
TX_NEW Sum of Age/Sex disaggregates 2017 2,498
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 3,272
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 14,105
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 12,707
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 409
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 344
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 8,966
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 2,988
TX_PVLS Numerator: Indication: Routine 2017 5,282
TX_PVLS Numerator: Indication: Targeted 2017 7,425
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 454
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 379
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 9,951
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,321
TX_PVLS_den Denominator: Indication: Routine 2017 5,854
TX_PVLS_den Denominator: Indication: Targeted 2017 8,251
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 54
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 28
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 74
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 316
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 116
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 35
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 59
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 36
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 859
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 318
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 1,962
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,615
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 25
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 71
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 37
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 99
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 421
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 153
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 48
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 40
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 82
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 52
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,143
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 425
VMMC_CIRC By Age: 10-14 2017 86,134
VMMC_CIRC By Age: 15-19 2017 36,570
VMMC_CIRC By Age: 20-24 2017 13,118
VMMC_CIRC By Age: 25-29 2017 36,445
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 172,267
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 172,267
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 172,267
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 135,822
Cross Cutting Budget Categories and Known Amounts Total: $760,000
Condoms: Policy, Tools, and Services $100,000
Gender: Gender Based Violence (GBV) $610,000
GBV Prevention
Gender: Gender Equality $50,000
Changing harmful gender norms and promoting positive gender norms